Perphenazine for schizophrenia

Cochrane Database of Systematic Reviews

Volumn 2015, Issue 3, 2015, Pages

  Hartung, Benno ^a   Sampson, Stephanie ^b   Leucht, Stefan ^c  

^a UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^b UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; BROMPERIDOL; CHLORPROMAZINE; CLOCAPRAMINE; CLOPENTHIXOL; CLOTIAPINE; CLOZAPINE; HALOPERIDOL; LOXAPINE; MOPERONE; NEUROLEPTIC AGENT; OLANZAPINE; PECAZINE; PENFLURIDOL; PERPHENAZINE; PLACEBO; PROCHLORPERAZINE; QUETIAPINE; RISPERIDONE; SULPIRIDE; THIORIDAZINE; TIMIPERONE; TIOTIXENE; TRIFLUOPERAZINE; TRIFLUPROMAZINE; ZIPRASIDONE; ZOTEPINE; ZUCLOPENTHIXOL;

DISEASE SEVERITY; DRUG EFFECT; DRUG RESPONSE; DRUG SAFETY; DYSTONIA; EUROPE; HEALTH CARE UTILIZATION; HEALTH ECONOMICS; HOSPITALIZATION; HUMAN; JAPAN; MENTAL HEALTH; META ANALYSIS; MORTALITY; NORTH AMERICA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RELAPSE; REVIEW; SCANDINAVIA; SCHIZOPHRENIA; SIDE EFFECT; SYSTEMATIC REVIEW; MENTAL DISORDERS;

ANTIPSYCHOTIC AGENTS; HUMANS; MENTAL DISORDERS; PERPHENAZINE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SCHIZOPHRENIA;

EID: 84942811696     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD003443.pub3     Document Type: Review

References (255)

1. Amakusa T, Majima T. The comparison of therapeutic effects of FK-880 (sulpiride) and perphenazine in schizophrenia by a double-blind controlled study. Juntendo Igako 1973;19(2):239-49.
2. Bennett JL, Kooi KA. Five phenothiazine derivates. evaluation and toxicity studies. Archives of General Psychiatry 1961;4:413-8.
3. CATIE - Schizophrenia Trial. National Institute of Mental Health (NIMH), NCT00014001 Study start: December 2000; Study completion: December 2004.
4. Addington D. Impact of second generation antipsychotic drugs and perphenazine on depressive symptoms in a randomized trial of treatment for chronic schizophrenia. Proceedings of the 164th annual general meeting of the American Psychiatric Association; 2011 May 14-18; Honolulu, Hawaii 2011. [: CATIE]
5. Addington DE, Mohamed S, Rosenheck RA, Davis SM, Stroup TS, McEvoy JP, et al. Impact of second-generation antipsychotic drugs and perphenazine on depressive symptoms in a randomized trial of treatment for chronic schizophrenia. Journal of Clinical Psychiatry 2011; Vol. 72, issue 1:75-80. [: CATIE]
6. Anon. Antipsychotic medications for schizophrenia on equal footing in improving patients' thinking skills. Science Update 2007:1. [ANON: 2007 h]
7. Ascher-Svanum H, Nyhuis AW, Faries DE, Heiler L, Kinon BJ. Treatment discontinuation following randomization to open-label olanzapine, risperidone or typical antipsychotic drugs during a one-year treatment for schizophrenia. Clinical Schizophrenia & Related Psychoses. United States, 2008; Vol. 2, issue 3:226-34. [ASCHER-SVANUM: 2008]
8. Bick P, Knoesen N, Castle D. Clinical implications of the CATIE schizophrenia trials: day-to-day management lessons for Australasian psychiatrists. Australasian Psychiatry 2007; Vol. 15, issue 6:465-9. [CATIE: 2003]
9. Essock SM, Covell NH, Davis SM, Stroup TS, Rosenheck RA, Lieberman JA. Effectiveness of switching antipsychotic medications. American Journal of Psychiatry 2006; Vol. 163, issue 12:2090-5. [ESSOCK: 2006 b]
10. Gutierrez-Suela F. Selection of antipsychotic drugs in a psychiatric hospital based on the results of CATIE study. Farmacia Hospitalaria 2008; Vol. 32, issue 2:83-90. [GUTIERREZ-SUELA: 2008]
11. Haddad PM, Dursun S. Selecting antipsychotic drugs in schizophrenia: lessons from CATIE. Journal of Psychopharmacology (Oxford, England) 2006; Vol. 20, issue 3:332-4. [CATIE: 2003]
12. Hermes E, Nasrallah H, Davis V, Meyer J, McEvoy J, Goff D, et al. The association between weight change and symptom reduction in the CATIE schizophrenia trial. Schizophrenia Research 2011; Vol. 128, issue 1-3:166-70. [: CATIE]
13. Hermes E, Rosenheck R. Choice of randomization to clozapine versus other second generation antipsychotic drugs in the CATIE schizophrenia trial. Journal of Psychopharmacology (Oxford, England) 2012; Vol. 26, issue 9:1194-200. [: CATIE]
14. Hermes ED, Sokoloff D, Stroup TS, Rosenheck RA. Minimum clinically important difference in the positive and negative syndrome scale with data from the clinical antipsychotic trials of intervention effectiveness (CATIE). Journal of Clinical Psychiatry 2012; Vol. 73, issue 4:526-32. [: CATIE]
15. Jin Y, Pollock BG, Coley K, Miller D, Marder SR, Florian J, et al. Population pharmacokinetics of perphenazine in schizophrenia patients from CATIE: impact of race and smoking. Journal of Clinical Pharmacology 2010; Vol. 1, issue 1:73-80. [: CATIE]
16. Keefe R. Neurocognitive efficacy in patients with chronic schizophrenia. European Neuropsychopharmacology 2006;16(Suppl 4):S577.
17. Keefe RSE, Bilder RM, Davis SM, Harvey PD, Palmer BW, Gold JM, et al. CATIE Investigators, Neurocognitive Working Group. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE trial. ArchIves of General Psychiatry 2007;64(6):633-47.
18. Levine SZ, Rabinowitz J, Ascher-Svanum H, Faries D, Lawson T. Extent of attaining and maintaining symptom remission by antipsychotic medication in the treatment of chronic schizophrenia: Evidence from the CATIE study. Value in Health 2011; Vol. 7, issue 7:14. [: CATIE]
19. Levine SZ, Rabinowitz J, Ascher-Svanum H, Faries DE, Lawson AH. Extent of attaining and maintaining symptom remission by antipsychotic medication in the treatment of chronic schizophrenia: Evidence from the CATIE study. Schizophrenia Research 2011; Vol. 133, issue 1-3:42-6. [: CATIE]
20. Lieberman JA, Stroup TS, McEvoy JP, Swartz MA, Rosenheck RA, Perkins DO, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New England Journal of Medicine 2005;353(12):1209-23.
21. Lin LA. Comparing antipsychotic treatments for schizophrenia: A health state approach. Dissertation Abstracts International: Section B: The Sciences and Engineering 2012; Vol. 73, issue 2-B:863. [: CATIE]
22. McEvoy JP, Lieberman JA, Stroup TS, Davis SM, Meltzer HY, Rosenheck RA, et al. CATIE Investigators. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. American Journal of Psychiatry 2006;163(4):600-10. [DOI: ]
23. Meyer JM, McEvoy JP, Davis VG, Goff DC, Nasrallah HA, Davis SM, et al. Inflammatory markers in schizophrenia: comparing antipsychotic effects in phase 1 of the clinical antipsychotic trials of intervention effectiveness study. Biological Psychiatry 2009; Vol. 66, issue 11:1013-22. [: CATIE]
24. Miller DD, Caroff SN, Davis SM, Rosenheck RA, McEvoy JP, Saltz BL, et al. Extrapyramidal side-effects of antipsychotic drugs in a randomised trial. British Journal of Psychiatry 2008; Vol. 193, issue 4:279-88. [CATIE: 2003]
25. Nasrallah HA. Metabolic findings from the CATIE trial and their relation to tolerability. CNS Spectrums 2006; Vol. 11, issue 7 Suppl 7:32-9. [: CATIE]
26. Olfson M, Ascher-Svanum H, Faries DE, Marcus SC. Predicting psychiatric hospital admission among adults with schizophrenia. Psychiatric Services (Washington, D.C.) 2011; Vol. 62, issue 10:1138-45. [: CATIE]
27. Penn DL, Keefe RSE, Davis SM, Meyer PS, Perkins DO, Losardo D, et al. The effects of antipsychotic medications on emotion perception in patients with chronic schizophrenia in the CATIE trial. Schizophrenia Research 2009; Vol. 115, issue 1:17-23. [: CATIE]
28. Perlick DA, Rosenheck RA, Kaczynski R, Swartz MS, Canive JM, Lieberman JA. Impact of antipsychotic medication on family burden in schizophrenia: longitudinal results of CATIE trial. Schizophrenia Research 2010; Vol. 116, issue 2-3:118-25. [: CATIE]
29. Resnick SG, Rosenheck RA, Canive JM, Souza CD, Stroup TS, McEvoy J, et al. Employment outcomes in a randomized trial of second-generation antipsychotic drugs and perphenazine in the treatment of individuals with schizophrenia. Journal of Behavioural Health Services and Research 2008;35(2):215-25.
30. Rosenheck R, Swartz M, McEvoy J, Stroup TS, Davis S, Keefe RS, et al. Second-generation antipsychotic drugs: Reviewing the cost-effectiveness component of the CATIE trial. Expert Review of Pharmacoeconomics & Outcomes Research 2007; Vol. 7, issue 2:103-11. [: CATIE]
31. Rosenheck RA, Davis VG, Davis SM, Stroup S, McEvoy J, Swartz M, et al. Can a nonequivalent choice of dosing regimen bias the results of flexible dose double blind trials? The CATIE schizophrenia trial. Schizophrenia Research 2009; Vol. 113, issue 1:12-8. [: CATIE]
32. Rosenheck RA, Leslie DL, Sindelar J, Miller EA, Lin H, Stroup TS, et al. Cost-effectiveness of second-generation antipsychotic drugs and perphenazine in a randomized trial of treatment for chronic schizophrenia. American Journal of Psychiatry 2006;163(12):2080-9.
33. Schulte PFJ, De Haan L. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. Tijdschrift voor Psychiatrie 2006;48(3):243-4.
34. Stroup S, Appelbaum P, Swartz M, Patel M, Davis S, Jeste D, et al. Decision-making capacity for research participation among individuals in the CATIE schizophrenia trial. Schizophrenia Research 2005; Vol. 80, issue 1:1-8. [: CATIE]
35. Stroup TS. Comparison of ziprasidone versus other atypical drugs in prospectively defined, unresponsive patients. Proceedings of the 159th Annual Meeting of the American Psychiatric Association; 2006 May 20-25, Toronto, Canada. 2006.
36. Stroup TS, Leiberman JA, McEvoy JP, Swartz MS, Davis SM. Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. American Journal of Psychiatry 2006;163:611-22.
37. Stroup TS, Lieberman JA, McEvoy JP, Davis SM, Swartz MS, Keefe RSE, et al. Results of phase 3 of the CATIE schizophrenia trial. Schizophrenia Research 2009; Vol. 107, issue 1:1-12. [CATIE: 2003]
38. Stroup TS, Lieberman JA, McEvoy JP, Swartz MS, Davis SM, Capuano GA, et al. Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study. American Journal of Psychiatry 2007;164(3):415-27.
39. Stroup TS, McEvoy JP, Swartz MS, Byerly MJ, Glick ID, Canive JM, et al. The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol developme. Schizophrenia Bulletin 2003;29(1):15-31.
40. Swartz MS, Perkins DO, Stroup TS, Davis SM, Capuano G, Rosenheck RA, et al. Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study. American Journal of Psychiatry 2007;164(3):428-36.
41. Swartz MS, Stroup TS, McEvoy JP, Davis SM, Rosenheck RA, Keefe RS, et al. What CATIE found: results from the schizophrenia trial. Psychiatry Online May 2008;59(5):500-06.
42. Swartz MS, Wagner HR, Swanson JW, Stroup TS, McEvoy JP, Reimherr F, et al. The effectiveness of antipsychotic medications in patients who use or avoid illicit substances: Results from the CATIE study. Schizophrenia Research 2008;100(1-3):39-52.
43. Tsai HT, Caroff SN, Miller DD, McEvoy J, Lieberman JA, North KE, et al. A candidate gene study of tardive dyskinesia in the CATIE schizophrenia trial. American Journal of Medical Genetics 2010; Vol. 153B, issue 1:336-40. [: CATIE]
44. Wessels AM, Bies RR, Pollock BG, Schneider LS, Lieberman JA, Stroup S, et al. Population pharmacokinetic modeling of ziprasidone in patients with schizophrenia from the CATIE study. Journal of Clinical Pharmacology 2011; Vol. 51, issue 11:1587-91. [: CATIE]
45. Chouinard G, Annable L, Serrano M, Albert JM, Charette R. Amitriptyline-perphenazine interaction in ambulatory schizophrenic patients. A controlled study of drug interaction. Archives of General Psychiatry 1975;32:1295-307.
46. Chouinard G, Annable L. Phenothiazine-induced ECG abnormalities. Effect of a glucose load. Archives of General Psychiatry 1977;34(8):951-4.
47. Collins AD, Dundas J. A double-blind trial of amitriptyline-perphenazine, perphenazine and placebo in chronic withdrawn inert schizophrenics. British Journal of Psychiatry 1967;113:1425-9.
48. Dehnel LL, Vestre ND, Schiele BC. A controlled comparison of clopenthixol and perphenazine in a chronic schizophrenic population. Current Therapeutic Research, Clinical and Experimental 1968; Vol. 10, issue 4:169-76. [DEHNEL: 1968]
49. Eckmann F, Weber J. No English version available [Vergleich zwischen Perphenazin und Benperidol. Eine kontrollierte Doppelblind-Studie]. unpublished manuscript 1984.
50. Fruensgaard K, Wollenberg J, Hansen KM, Fensbo C, Sihm F. Loxapine versus perphenazine in psychotic patients. A double-blind, randomized, multicentre trial. Current Medical Research and Opinion 1978;5(8):601-7.
51. Hanlon TE, Nussbaum K, Wittig B, Hanlon DD, Kurland AA. The comparative effectiveness of amitriptyline, perphenazine, and their combination in the treatment of chronic psychotic female patients. Journal of New Drugs 1964;4:52-60.
52. Hanlon TE, Michaux MH, Ota KY, Shaffer JW, Kurland AA. The comparative effectiveness of eight phenothiazines. Psychopharmacologia 1965;7(2):89-106.
53. Hoyberg OJ, Fensbo C, Remvig J, Lingjaerde O, Sloth Nielsen M, Salvesen I. Risperidone versus perphenazine in the treatment of chronic schizophrenic patients with acute exacerbations. Acta Psychiatrica Scandinavica 1993;88(6):395-402.
54. Imai H, Nakamura M, Fukui Y, et al. Comparison of efficacy of zotepine and perphenazine in schizophrenia by double-blind, controlled study. Shinkei Seishin Yakuri 1980;2(3):285-99.
55. Itoh H, Okamoto M, Miura S, Suzuki Y, Takemasa K, Shigeta M, et al. A comparison between the clinical effectiveness of a dibenzothiazepine derivative and a phenothiazine derivative in schizophrenia. A controlled double blind study using clotiapine (W 130) and perphenazine. Seishin Igaku 1969;11(6):465-75.
56. Itoh H, Miura S, Asai M, et al. Comparison of thiothixene and perphenazine in schizophrenic patients using double-blind technique. Seishin Igaku 1969;11(4):284-97.
57. Itoh H, Okamoto M, Miura S, et al. Comparison of a butyrophenone derivative (methylperidol) and a phenothiazine derivative (perphenazine) in schizophrenic patients using double-blind technique: statistical analysis by sequential method and wilcoxon test. Seishin Igaku 1969;11(2):131-42.
58. Itoh H, Miura S, Yagi G, Ogita K, Ohtsuka N, Koga Y, et al. Comparison of clinical effects of penfluridol, a long-acting oral neuroleptic, and perphenazine in schizophrenia using double-blind technique. Rinsho Hyoka 1976;4(1):101-29.
59. Bristol-Myers S. A multicenter, randomized, double-blind study of flexible doses of aripiprazole versus perphenazine in the treatment of patients with treatment-resistant schizophrenia. http://www.clinicalstudyresults.org/ 2004. [BRISTOL-MYERS: 2004]
60. Gismondi R, Meltzer H, Kujawa M, Carson W, Stringfellow J, Iwamoto T, et al. Aripiprazole versus perphenazine in treatment-resistant schizophrenia. Proceedings of the 24th Collegium Internationale Neuro-Psychopharmacologicum Congress; 2004 June 20-24; Paris, France 2004. [KANE: 2003 a]
61. Kane J, Carson W, Kujawa M, Stringfellow J, Marcus R, Sanchez R, et al. Aripiprazole in treatment-resistant schizophrenia: a 6-week double- blind comparison study versus perphenazine. Schizophrenia Research 2004; Vol. 67, issue 1:155-6. [KANE: 2003 a]
62. Kane J, Carson WH, Kujawa M, Stringfellow J, Marcus R, Sanchez R, et al. Aripiprazole in treatment-resistant schizophrenia: A 6-week double-blind comparison study versus perphenazine. Conference proceedings. Elsevier Science Bv, 2004:155-6. [KANE: 2004a]
63. Kane J, McQuade R, Jody D, Carson W, Kujawa M, Stringfellow J, et al. Aripiprazole in treatment-resistant schizophrenia: a 6-week double-blind comparison study vs perphenazine. Conference proceedings: 12th Biennial Winter Workshop on Schizophrenia, Davos, Switzerland 2004. [KANE: 2003 a]
64. Kane JM, Meltzer HY, Carson WH Jr, McQuade RD, Marcus RN, Sanchez R. Aripiprazole Study Group. Aripiprazole for treatment-resistant schizophrenia: results of a multicenter, randomized, double-blind, comparison study versus perphenazine. Journal of Clinical Psychiatry 2007; Vol. 68, issue 2:213-23. [KANE: 2007]
65. McQuade R, Jody D, Kane J, Carson W, Kujawa M, Stringfellow J, et al. Efficacy and safety of aripiprazole versus perphenazine in treatment-resistant schizophrenia. European Neuropsychopharmacology 2003; Vol. 13, issue 4:S326. [KANE: 2003 a]
66. Modell S, Jody D, Kujawa M, Carson W, Stringfellow J, Iwamoto T, et al. Efficacy of aripiprazole and perphenazine in severe schizophrenia resistant to treatment with atypical antipsychotic drugs. European Neuropsychopharmacology 2004; Vol. 14, issue Suppl 3:S265. [KANE: 2003 a]
67. Sanchez R, Meltzer HY, Marcus RN, Stringfellow J, Carson WH, Kane JM. Aripiprazole versus perphenazine in Treatment - Resistant Schizophrenia. Schizophrenia Bulletin 2005; Vol. 31:502. [KANE: 2003 a]
68. Kurihara M, Ito H, Kato N, et al. Clinical evaluation of clocapramine (clofekton) in schizophrenia: a double blind comparison of clocapramine, haloperidol and perphenazine. Rinsho Seishin Igaku 1983;12(4):519-38.
69. Kurland AA, Hanlon TE, Tatom MH, Ota KY, Simopoulos AM. The comparative effectiveness of six phenothiazine compounds, phenobarbital and inert placebo in the treatment of acutely ill patients: global measures of severity of illness. Journal of Nervous and Mental Disease 1961;133(1):1-18.
70. Kurland AA, Hanlon TE, Tatom MH, Simopoulos AM. Comparative studies of the phenothiazine tranquilizers: methodological and logistical considerations. Journal of Nervous and Mental Disease 1961;132:61-74.
71. Lepola U, Koskinen T, Rimon R, Salo H, Gordin A. Sulpiride and perphenazine in schizophrenia. A double-blind clinical trial. Acta Psychatrica Scandinavica 1989;80(1):92-6.
72. Eli Lilly, Company. HGBJ: olz v perphenazine. Eli Lilly and Company 2001.
73. Naukkarinen H, Rimon R, Katila H, Riihikangas R, Heikkilä L. Olanzapine and perphenazine in schizophrenia. Schizophrenia Research 2000;41(1):190.
74. Rimon RH. Olanzapine versus perphenazine in the treatment of schizophrenia: a double-blind study. Schizophrenia research 2004;67(1):164-5.
75. Remvig J, Larsen H, Rask P, Skausig OB, Skov S, Strömgren LS. Zuclopenthixol and perphenazine in patients with acute psychotic states. A double-blind multicentre study. Pharmacopsychiatry 1987;20:147-54.
76. Sun Z, Liu B, Li Z, Zhang D, et al. Clozapine combined with perphenazine in the treatment of schizophrenia. Hebei Mental Health 2000; Vol. 13, issue 2:142-4. [SUN: 2000 (Perp)]
77. Takahashi R, Inanaga K, Samejima K, Sarai K, Asada S, Otsuki S, et al. Comparison of efficacy of a new butyrophenone derivative, timiperone and perphenazine in schizophrenia by a multicentre controlled study. Journal of International Medical Research 1982;10(4):257-67.
78. Van Praag HM, Korf J, Dolc LCW. Clozapine versus perphenazine: the value of the biochemical mode of action of neuroleptics in predicting their therapeutic activity. British Journal of Psychiatry 1976;129:547-55.
79. Wang XD, Wang YH, Feng TM, Liu ML, Zhang SX. Controlled study of risperidone in elderly treatment of first-episode schizophrenia. Journal of Psychiatry 2008;21(2):141.
80. Wang RF, Yu X, Song ZD. Schizophrenia olanzapine and perphenazine in the treatment of positive symptoms. Journal of Psychiatry 2008;21(6):423-4.
81. Wang X, Wu J, Chen Z, Zhang JF, et al. Elderly first controlled study of quetiapine in the treatment of schizophrenia. Journal of Psychiatry 2008;21(6):463-4.
82. Woggon B. Effects and side-effects of bromperidol in comparison with other antipsychotic drugs. Acta Psychiatrica Belgica 1978;78(1):155-72.
83. Woggon B, Angst J. Double-blind comparison of bromperidol and perphenazine. International Pharmacopsychiatry 1978;13:165-76.
84. Zhang JL, Zhang J, Shen B. Aripiprazole orally disintegrating tablets in the treatment of schizophrenia in old age were observed. Chinese Journal of Modern Drug Application 2010;4(14):119-20.
85. Affleck JW, Cooper AJ, Forrest AD, Smythies JR, Zealley AK. Penicillamine and schizophrenia - a clinical trial. British Journal of Psychiatry 1969;115(519):173-6.
86. Ahlfors UG, Dencker SJ, Gravem A, Remvig J. Clopenthixol decanoate and perphenazine enanthate in schizophrenic patients. A double-blind Nordic multicentre trial. Acta Psychiatrica Scandinavica Supplementum 1980;279:77-91.
87. Akimoto H, Shimazaki T, Shibata N, Sato Y, Takahashi R, Naruse H, et al. Current status of pharmacotherapy in schizophrenia. Folia Psychiatrica et Neurologica Japonica 1966;20(1):1-8.
88. Angst J, Woggon B. Clinical study on five depot neuroleptics. Comparison of effective profiles of fluphenazine decanoate, flusipirilene, penfluridol, perphenazine enanthate and pipothiazine palmitate. Arzneimittel Forschung 1975;25(2):267-70.
89. Anonymous. Schizophrenic and other psychotic reactions. Medical Letter 1966:15-6.
90. Asada S, Ishimaru T, Kubo S, Kodama H, Masuda K. Study of the clinical effects of sulpiride and perphenazine in 82 schizophrenic patients by the double-blind method [Etude des effets cliniques du sulpiride et de la perphenazine chez 82 schizophrenes par la methode du double aveugle]. Encephale 1976;2(1):73-83.
91. Bakke O. Clinical experience with depot neuroleptics. Acta Psychiatrica Scandinavica Supplementum 1973;246:32-41.
92. Bandelow B, Muller P, Frick U, Gaebel W, Linden M, Muller Spahn F, et al. Depressive syndromes in schizophrenic patients under neuroleptic therapy. European Archives of Psychiatry and Clinical Neuroscience 1992; Vol. 241, issue 5:291-5. [BANDELOW: 1992]
93. Becker RE. Evaluation of an amitriptyline-perphenazine combination in chronic schizophrenia. American Journal of Psychiatry 1970;127(6):827-131.
94. Bjerkelund C, Nitter-Hauge S, Jakobsen E. Perphenazine (trilafon) in the prophylaxis of nausea and vomiting following acute myocardial infarct. Acta Medica Scandinavica 1965;177:729-37.
95. Böhlau V, Weber J. No English title available [Therapie dementieller Prozesse bei Alterspatienten]. Therapiewoche 1985;35(47):5445-8.
96. Cannistra F, Abrams AA. Perphenazine in obstetrics. Evaluation of its use to replace an analgesic. Obstetrics and Gynecology 1959;14(3):337-41.
97. Ceskova E, Svestka J. Risperidone vs. perphenazine - a double-blind comparison and prolactine plasma levels [Risperidone gegen Rispehenazine - ein doppelt-blinder Vergleich und Prolaktin-Plasmaspiegel]. Psychiatria Danubina 1994;6(3-4):151-5.
98. Ceskova E, Svestka J. Efficacy and tolerability of risperidone in different dose levels [Ucinnost a snasenlivost risperidonu pri ruznem davkovani (sdeleni z praxe)]. Ceskoslovenska Psychiatrie 1996;92(1):50-6.
99. Clarke JMC. Amitriptyline and perphenazine (triptafen DA) in chronic pain. Anaesthesia 1981;36:210-2.
100. Cohen H. Trilafon in the treatment of chronically psychotic hospitalized patients. Prüfbericht, New York. E. Merck Darmstadt 1958.
101. Cooper SF, Dugal R, Elie R, Albert JM. Metabolic interaction between amitriptyline and perphenazine in psychiatric patients. Neuro-Psychopharmacology 1979;3:369-76.
102. Den Boer JA, Vahlne J-O, Post P, Heck AH, Daubenton F, Olbrich R. Ritanserin as add-on medication to neuroleptic therapy for patients with chronic or subchronic schizophrenia. Human Psychopharmacology 2000;15:179-89.
103. Dencker SJ, Gios I, Martenson E, Norden T, Nyberg G, Persson R, et al. A long-term cross-over pharmacokinetic study comparing perphenazine decanoate and haloperidol decanoate in schizophrenic patients. Psychopharmacology 1994;114(1):24-30.
104. Eklund KL. A double-blind comparison study between penfluridol and perphenazine in acute schizophrenic patients. Nordisk Psykiatrisk Tidsskrift 1976;30(5):384-91.
105. Erb RJ, Stoltman WP. Serum prolactin level increase in normal subjects following administration of perphenazine oral dosage forms: possible application to bioavailibility testing. Journal of Pharmaceutical Sciences 1982;71(8):883-8.
106. Eufe R, Wegener G. Double-blind comparison of two depot neuroleptics (perphenazine enanthate and flupentixol enanthate) in chronic schizophrenia. Nervenarzt 1979;50(8):534-9.
107. Fahn S. Treatment of choreic movements with perphenazine. Diseases of The Nervous System 1972;33:653-8.
108. Farzin D, Hosseini SH, Shafaat A. A randomized double blind clinical trial in famotidine adjuvant therapy in schizophrenia. Iranian Journal of Medical Sciences 2005; Vol. 30, issue 2:59-62. [FARZIN: 2005]
109. Fitzgerald CH. A double-blind comparison of haloperidol with perphenazine in acute psychiatric patients. Current Therapeutic Research 1969;11(8):515-9.
110. Galdi J, Bonato RB. Relationship of adverse drug reactions to length of hospital-stay in genetically subgrouped schizophrenics. Canadian Journal of Psychiatry 1988;33(9):816-8.
111. Gerlach J, Rasmussen PT, Hansen L, Kristjansen P. Antiparkinsonian agents and long-term neuroleptic treatment. Effect of G31.406, orphenadrine, and placebo on parkinsonism, schizophrenic symptoms, depression and anxiety. Acta Psychiatrica Scandinavica 1977;55(4):251-60.
112. Gerlach J. Tardive dyskinesia:Pathophysiological mechanisms and clinical trials. L'Encephale 1988;14:227-232.
113. Gerson IM, Chat E, Twigger NA. Clinical trial of a potentiated diketopiperazine derivative as a psychopharmacological agent for the treatment of psychotic patients. American Journal of Psychiatry 1964;121:179-81.
114. Gianelli A, Rabboni M, Zarattini F. No English title available [Profili clinici di azione, indicazioni preferenziali, effeti terapeutici e contraindicazioni di tre neuroletti depot in trial multicentro di confronto]. Rivista di Psichiatria 1990;25(1):7-24.
115. Hadlik J, Svestka J, Nahunek K, Rodova A. Controlled studies with thiothixene and perphenzine in schizophrenic psychoses [Kontrolovana studie s thiothixenem a perfenazinem u psychoz schizofrenniho okruhu]. Activitas Nervosa Superior 1970;12(1):60-1.
116. Hanlon T. Perphenazine-benztropine mesylate treatment of newly admitted psychiatric patients. Psychopharmacologia 1966; Vol. 9, issue 4:328-39. [HANLON: 1966]
117. Hansen BL, Elley J, Christensen RT, Laersen NE, Naestoft J, Hvidberg EF. Plasma levels of perphenazine and its metabolites during simultaneous treatment with anticholinergic drugs. British Journal of clinical Pharmacology 1979;7:75-80.
118. Haran T. Perphenazine (Fentazine) in the management of chronic schizophrenia. Journal of the Irish Medical Association 1960;46:135-8.
119. Holden JM, Itil TM, Keskiner A. Comparison of perphenazine and P-5227 in chronic schizophrenics: clinical and EEG effects. Journal of Clinical Pharmacology and the Journal of New Drugs 1969;9(3):163-75.
120. Hollister LE, Overall JE, Shelton J, Pennington V, Kimbell I, Johnson M. Drug therapy of depression. Archives of General Psychiatry 1967;17:486-93.
121. Hollister LE, Overall JE, Kimbell I Jr, Pokorny A. Specific indications for different classes of phenothiazines. Archives of General Psychiatry 1974;30(1):94-9.
122. Huang CL, Kurland AA. Perphenazine (trilafon) metabolism in psychotic patients. Archives of General Psychiatry 1964;10:639-46.
123. Jprn U. An intervention study of optimizing algorism-based pharmacological treatment for schizophrenia. http://www.umin.ac.jp/ctr/index.htm 2011. [: UMIN000004931]
124. Kaim SC, Klett CJ. Treatment of delirium tremens. A comparative evaluation of four drugs. Quarterly Journal of Studies 1972;33:1065-72.
125. Kaji S, Tsukada K, Hasegawa S, et al. Comparison of clinical efficacy of clocapramine and perphenazine for chronic schizophrenia by the double-blind study. Rinsyo Seisin Igaku 1974;3(8):867-74.
126. Kawakita Y. Drug therapy of acute schizophrenia. Saishin Igaku 1965;20(9):2440-8.
127. Kistrup K, Gerlach J, Aaes Jorgensen T, Larsen NE. Perphenazine decanoate and cis(z)-flupentixol decanoate in maintenance treatment of schizophrenic outpatients. Serum levels at the minimum effective dose. Psychopharmacology 1991;105(1):42-8.
128. Kline NS, Blair J, Cooper TB, Esser AH, Hackett E, Vestergaard P. A controlled seven year study of endocrine and other indices in drug treated chronic schizophrenics. Acta Psychiatrica Scandinavica Supplementum 1968;206:7-75.
129. Knudsen P, Hansen LB, Auken G, Waehrens J, Højholdt K, Larsen NE. Perphenazine decanoate vs. Perphenazine enanthate - efficacy and side-effects in a 6 week double-blind, comparative study of 50 drug monitored psychotic patients. Acta Psychiatrica Scandinavica Supplementum 1985;322:15-28.
130. Knudsen P, Hansen LB, Hojholdt K, Larsen NE. Long-term depot neuroleptic treatment with perphenazine decanoate. I. Efficacy and side effects in a 12 month study of 42 drug monitored psychotic patients. Acta Psychiatrica Scandinavica. Supplementum 1985; Vol. 322:29-40. [KNUDSEN: 1985 b]
131. Knudsen P, Hansen LB, Hojholdt K, Larsen NE. Long-term depot neuroleptic treatment with perphenazine decanoate. II. Different depot intervals in the last 6 months of a 12 month study of 42 drug monitored psychotic patients. Acta Psychiatrica Scandinavica. Supplementum 1985; Vol. 322:41-50. [KNUDSEN: 1985 b]
132. Kothari NJ, Saunders JC, Kline NS, Griffen JA. A comparison of perphenazine, proketazine, nialamide and MO-482 in chronic schizophrenics. American Journal of Psychiatry 1960;117:358-60.
133. Lapolla A. A double-blind evaluation of chlorpromazine versus a combination of perphenazine and amitriptyline. International Journal of Neuropsychiatry. 1967; Vol. 3, issue 5:403-5.
134. Levine J, Caspi N, Laufer N. Immediate effects of chlorpromazine and perphenazine following neuroleptic washout on word association of schizophrenic patients. Schizophrenia Research 1997;26:55-63.
135. Lindholm H, Gullberg B, Ohman A, Sedvall G. Effects of perphenazine injections on prolactin levels in plasma from schizophrenic women and men. Psychopharmacology 1978;57(1):1-4.
136. Linnoila M, George L, Guthrie S. Interaction between antidepressants and perphenazine in psychiatric inpatients. American Journal of Psychiatry 1982;139(10):1329-31.
137. Loprete FP, Palm C. Sleep in psychotic patients: a comparative clinical study. International journal of neuropsychiatry 1967;3(6):497-500.
138. Mason-Browne NL. Perphenazine - a drug modifying consciousness. American Journal of Psychiatry 1957;114:173-4.
139. Mason-Browne NL, Borthwick JW. Effect of perphenazine (trilafon) on modification of crude consciousness. Diseases of the Nervous System 1957;18:300-6.
140. Mazurek I, Loza B, Lecyk A. Atypical versus typical antipsychotic treatment prognosis based on veps and wcst scores in paranoid schizophrenia. European Neuropsychopharmacology 2003; Vol. 13, issue 4:S347. [LOZA: 2001]
141. Moore DC, Bridenbaugh LD, Ackeren van EG, Cole EV. Control of postoperative vomiting with perphenazine (trilafone): a double-blind study. Anesthesiology 1958;19:72-4.
142. Müller M. Pharmacokinetik/Bioavailibility Evaluation of Three Different perphenazine Formulations (Decentan) in 18 healthy volunteers [Pharmakokinetik/Bioverfügbarkeits-Studie mit drei verschiedenen Perphenazin-Zubereitungen (Decentan) mit 18 gesunden Freiwilligen]. E. Merck, Darmstadt 1994.
143. Nahunek K, Svestka J, Misurec J. Clinical comparison of methophenazine and perphenazine in schizophrenia. A controlled study. Effects on the photomyoclonic threshold [Klinischer Vergleich von Methophrenazin (Frenolon) und Perphenazin bei Schizophrenie. Kontrollierte Studie. Beeinflussung der photomyoklonischen Schwelle]. Activitas Nervosa Superior 1967;9(4):404-5.
144. Nahunek K, Svestka J, Rodova A. Clinical experience with octoclothepin in psychoses. Comparasion with perphenazine. Activitas Nervosa Superior 1968;10(3):339-40.
145. Nahunek K, Hadlik J, Svestka J, Rodova A, Vanysek J. A comparison of therapeutic effects of triperidol and perphenazine in schizophrenia [Srovnani lecebneho ucinku triperidolu s perphenazinem u schizofrenie]. Ceskoslovenska Psychiatrie. 1969;65(5):281-9.
146. Nahunek K, Hadlik J, Rodova A, Misurec J, Vanysek J. Comparison of triperidol with perphenazine in schizophrenic psychoses. Effect on the photomyoclonic threshold [Srovnani triperidolu s perphenazinem u schizofrennich psychoz vliv na fotomyoklonicky prah]. Activitas Nervosa Superior 1970;12(1):56-7.
147. Nahunek K, Svestka J, Rodova A. Comparison of the therapeutic effect of flupenthixol and perphenazine in schizophrenia. Activitas Nervosa Superior 1970;12(3):247-8.
148. Nahunek K, Svestka J, Misurec J, Rodova A. Clinical experience with clozapin [Klinicke zkusenosti s clozapinem]. Ceskoslovenska Psychiatrie 1975;71(1):11-20.
149. Nahunek K, Rodova A, Svestka J. Outline classification of neuroleptic drugs based on results of short-term control crossed studies in schizophrenia [Pokus o klasifikaci neuroleptik na podklade vysledku kradkodobych kontrolovanych zkrizenyich studii u schizofrenie]. Ceskoslovenska Psychiatrie 1976;72(2):104-14.
150. Nahunek K, Svestka J, Ceskova E. On the question of differences between therapeutic responses after particular neuroleptics in comparison to perphenazine in schizophrenics [Kotazce rozdilnosti terapeutickych odpovedi po jednotlivych neurolepticich ve srovnani s perphenazinem u schizofrennich nemocnych]. Ceskoslovenska Psychiatrie 1981;77(1):25-30.
151. Nahunek K, Svestka J, Ceskova E. Controlled 'comparison' of perphenazine with perphenazine in schizophrenia - a methodical check of a double-blind cross-over design. Activitas Nervosa Superior 1980;22(3):154-5.
152. Nordic Dyskinesia Study Group. Effect of different neuroleptics in tardive dyskinesia and parkinsonism. A video-controlled multicentre study with chlorprothixene, perphenazine, haloperidol and haloperidol + biperiden. Psychopharmacology 1986;90(4):423-9.
153. O'Reilly PO, Wojcicki HM, Hrychuk W, Keogh RP. Perphenazine (Trilafon) in the treatment of pschoses. Canadian Medical Association Journal 1957;77:952-5.
154. Oltman JE, Friedman S. Perphenazine-amitriptyline in the treatment of schizophrenia. American Journal of Psychiatry 1966;123(5):607-9.
155. Omerov M, Wistedt B, Bolvig HL, Larsen NE. The relationship between perphenazine plasma levels and clinical response in acute schizophrenia. Progress in Neuropsychopharmacology and Biological Psychiatry 1989;13(1-2):159-66.
156. Opjordsmoen S, Brunsvik S, Melle I, Dahl A, Friis S, Haahr U, et al. A comparison between novel and traditional antipsychotic drugs as first-line medication in early psychosis. Second international conference on early psychosis 2000, 31 March - 2 April. [OPJORDSMOEN: 2000]
157. Pfeiffer CC, Goldstein L, Murphree HB, Sugerman AA. Time-series frequency analysis, and electrogenesis of the EEGs of normals and psychotics before and after drugs. American Journal of Psychiatry. 1965;122:1147-55.
158. Prien RF, Gillis RD, Caffey EM. Intermittent pharmacotherapy in chronic schizophrenia. Hospital and Community Psychiatry 1973;24(5):317-322.
159. Prusoff BA, Williams DH, Weissman MM, Astrachan BM. A controlled clinical trial of amitriptyline added to perphenazine in the treatment of depressed schizophrenics. Psychopharmacology Bulletin 1979;15(2):80-1.
160. Rapp W. Preliminary study of perphenazine enanthate in the treatment of chronic schizophrenia. Pharmakopsychiatrie Neuropsychopharmakologie 1972;5:205-14.
161. Rapp W, Hellbom E, Norrman O, Palm U, et al. A double blind crossover study comparing haloperidol decanoate and perphenazine enanthate. Current Therapeutic Research 1986;39(5):665-70.
162. Rappaport M. Competing voice messages. Effects of a message load and drugs on the ability of acute schizophrenics to attend. Archives of General Psychiatry 1967;17:97-103.
163. Rappaport M. Attention to competing voice messages by nonacute schizophrenic patients. Effects of message load, drugs, dosage levels and patient background. Journal of Nervous and Mental Disease 1968;146(5):404-11.
164. Reznik I, Sirota P. Treatment of obsessive and compulsive symptoms in schizophrenia with SSRI's and neuroleptics: a randomized controlled trial. 21st Congress of Collegium Internationale Neuro-psychopharmacologicum, Glasgow, Scotland, UK 1998.
165. Reznik I, Sirota P, Psych M. Obsessive and compulsive symptoms in schizophrenia: a randomized controlled trial with fluvoxamine and neuroleptics. Journal of Clinical Psychopharmacology 2000;20(4):410-6.
166. Rickels K, Csanalosi I, Werblowsky J, Weise CC, Weinstock R, Brown AS. Amitriptyline-perphenazine and doxepin in depressed outpatients: a controlled double-blind study. Journal of Clinical Psychiatry 1982;43(10):419-22.
167. Ritter RM, Davidson DE. Haloperidol for acute psychiatric emergencies. A double-blind comparison with perphenazine in acute alcoholic psychosis. Southern Medical Journal 1971;64(2):249-50.
168. Rodova A, Nahunek K, Svestka J. Comparison of the therapeutic results of clothiapin and perphenazine in schizophrenia. Activitas Nervosa Superior 1971;13(3):171-3.
169. Rodova A, Svestka J, Nahunek K, Ceskova E. A blind comparison of clozapine and perphenazine in schizophrenics. Activitas Nervosa Superior 1973;15(2):94-5.
170. Scurr CF, Robbie DS. Trials of perphenazine in the prevention of postoperative vomiting. British Medical Journal 1958;1:922-3.
171. Shalev A, Hermesh H, Rothberg J, Munitz H. Poor neuroleptic response in acutely exacerbated schizophrenic patients. Acta Psychiatrica Scandinavica 1993;87(2):86-91.
172. Sharpley P, Heistad G, Schiele BC. Comparison of butaperazine and perphenazine: a double-blind controlled study. Psychopharmacology 1964; Vol. 13:209-16. [SHARPLEY: 1964 a]
173. Shiloh R, Zemishlany Z, Aizenberg D, Valevski A, Bodinger L, Munitz H, et al. Mianserin or placebo as adjuncts to typical antipsychotic drugs in resistant schizophrenia. International Clinical Psychopharmacology 2002; Vol. 17, issue 2:59-64. [SHILOH: 2002]
174. Silver H, Barash I, Aharon N, Kaplan A, Poyurovsky M. Fluvoxamine augmentation of antipsychotic drugs improves negative symptoms in psychotic chronic schizophrenic patients: a placebo-controlled study. International Clinical Psychopharmacology 2000;15(5):257-61.
175. Simopoulos AM, Pinto A, Uhlenhuth EH, Mcgee J. Old wine in new bottles: decreased hostility in chronic psychotic inpatients treated with diphenylhydantoin (Dilantin). 5th World Congress of Psychiatry, Ciudad de Mexico. 1971:526.
176. Simpson GM, Krakov L, Kunz-Bartholini E. A controlled trial of combined medications on behavioral and extrapyramidal effects. Acta Psychiatrica Scandinavica Supplementum 1970;212:20-7.
177. Smith JA, Christian D, Mansfield E, Figaredo A. A graphic comparison of five phenothiazines. American Journal of Psychiatry 1959;116:392-9.
178. Spiker DG, Cofsky Weiss J, Dealy RS, Griffin SJ, Hanin I, Neil JF, et al. The pharmacological treatment of delusional depression. American Journal of Psychiatry 1985;142:430-6.
179. Sun S, Liu Y, Long JL, Wang L. Venlafaxine extended release tablets on schizophrenia cognitive function] Google Translate. Chinese Journal of Health Psychology. 2010; Vol. 18, issue 4:394-6.
180. Sun J, Xie S, Nisu L, Wang X, Shang X, et al. acute schizophrenic inpatients converted to aripiprazole treatment efficacy and safety of] Google Translate. Shandong Archives of Psychiatry 2010; Vol. 23, issue 3:179-81.
181. Svestka J, Nahunek K. Controlled comparative study of methylperidol and perphenazine in schizophrenic psychoses [Kontrolovane srovnani metylperidolu s perfenazinem u psychoz schizofrenniho ikruhu]. Activitas Nervosa Superior 1970;12(1):57-8.
182. Svestka J, Nahunek K. A comparison of pimozide with perphenazine in the treatment of acute schizophrenic psychoses. Activitas Nervositas Superior 1972;14(2):93-4.
183. Svestka J, Rodova A, Nahunek K. Comparison of the short-term therapeutic effect of oxyprothepine and perphenazine in schizophrenic patients. A controlled study. Activitas Nervosa Superior 1973;15(2):103-4.
184. Svestka J, Nahunek K, Rodova A, Ceskova E. A controlled comparison of oxypertine and perphenazine in schizophrenic psychoses. Activitas Nervosa Superior 1974;16(3):165-6.
185. Svestka J, Nahunek K, Rodova A, Ceskova E. The position of trifluoperazine in the group of neuroleptics (a controlled clinical comparative study). Activitas Nervosa Superior 1975;17(3):208.
186. Svestka J, Nahunek K, Ceskova E, Rysanek R, Balsíková, J. Controlled cross over comparison of isofloxythepin and perphenazine in the treatment of schizophrenic psychoses. Activitas Nervosa Superior 1989;31(1):32-4.
187. Svestka J, Ceskova E, Rysanek R, Nahunek K. Controlled cross over comparison of carbamazepine with perphenazine in schizophrenic psychoses. 31st Annual Psychopharmacology Meeting (1989, Jesenik, Czechoslovakia). Activitas Nervosa Superior 1989;31(4):276-7.
188. Svestka J, Rysanek R, Nahunek K, Ceskova E. Therapeutic results in schizophrenic and schizoaffective psychoses with sulpiride (Eglonyl Alkaloid), as compared with perphenazine (Perfenazin Spofa) [Vysledky lecby schizofrennich a schizoafektivnich nemocnych sulpiridem (Eglonyl Alkaloid) ve srovnani s perfenazinem (Perfenazin Spofa)]. Ceskoslovenska Psychiatrie 1990;86(3):145-56.
189. Syvalahti EK, Taiminen T, Saarijarvi S, Lehto H, Niemi H, Ahola V, et al. Citalopram causes no significant alterations in plasma neuroleptic levels in schizophrenic patients. Journal of International Medical Research 1997;25(1):24-32.
190. Tegeler J, Floru L. A comparative study of the longacting neuroleptics perphenazine enanthate and flusipirilene. Pharmakopsychiatrie Neuropsychopharmakologie 1979;12(5):357-65.
191. Wang X, Yin J, Yang L, Li W, Wu G, et al. Double-blind controlled side reaction of the L-stepholidine the treatment of schizophrenia and Nursing Strategy. Shandong Archives of Psychiatry 2001; Vol. 14, issue 3:204-6.
192. Whittaker CB, Hoy RM. Withdrawal of perphenazine in chronic schizophrenia. British Journal of Psychiatry 1963;109:422-7.
193. Wolf J, Janssen F, Lublin H, Salokangas RKR, Allain H, Smeraldi E, et al. A prospective, multicentre, open-label study of aripiprazole in the management of patients with schizophrenia in psychiatric practice in Europe: Broad Effectiveness Trial with Aripiprazole in Europe (EU-BETA). Current Medical Research and Opinion 2007; Vol. 23, issue 10:2313-23. [WOLF: 2007]
194. Yagi G. A double-blind controlled study on the usefulness of carpipramine-chlorpromazine combination in the pharmacotherapy of chronic schizophrenic patients. Rinsho Hyoka (Clinical Evaluation) 1976;4(3):351-403.
195. Zhong C, Guozhang J, Duochen W. A double-blind comparison trial of 1-stepholidine and perphenazine in treatment of schizophrenia. 7th World Congress of Biological Psychiatry, Berlin, Germany. Suppl 1 2001; Vol. 2. [ZHONG: 2001]
196. Zhu S, Liu Y, Sun S, Wang L. Psychological care on cognitive function in patients with chronic schizophrenia, the impact of (Google Translate). China Practical Medicine 2009; Vol. 4, issue 22:190-2.
197. Casey JF, Lasky JJ, Klett CJ, Hollister LE. Treatment of schizophrenic reactions with phenothiazine derivates. A comparative study of chlorpromazine, triflupromazine, mepazine, prochlorperazine, perphenazine and phenobarbital. American Journal of Psychiatry 1960;117:97-105.
198. Covell NH, Weissman EM, Essock SM. Weight gain with clozapine compared to first generation antipsychotic medications. Schizophrenia bulletin 2004; Vol. 30, issue 2:229-40. [COVELL: 2004]
199. Ferziger R, Alphs L, Turner N, Mao L, Rodriguez S, Dixon L, et al. A multicenter effectiveness study of paliperidone palmitate vs oral antipsychotic drugs for people with schizophrenia recently released from jail: Study rationale and methodology. Neuropsychopharmacology 2010; Vol. 35:S101-S2. [FERZIGER: 2010 a]
200. Ferziger R, Alphs L, Turner N, Mao L, Rodriguez S, Dixon L, et al. A multicenter effectiveness study of paliperidone palmitate vs oral antipsychotic drugs for people with schizophrenia recently released from jail: Study rationale and methodology. Proceedings of the 49th Annual meeting of the Americam College of Neuropsychopharmacology; 2010 Dec 5-9; Miami, Florida 2010. [FERZIGER: 2010]
201. Freedman DX, Jong de J. Thresholds for drug-induced akathisia. Journal of American Psychiatry 1961;117:930-1.
202. Freyhan FA. Therapeutic implications of differential effects of new phenothiazine compounds. American Journal of Psychiatry 1959;116:577-85.
203. Goldstein BJ, Brauzer B, Clyde DJ, Caldwell JM. The differential prediction of response to two anti-psychotic drugs. Psychosomatics 1969;10(3):193-7.
204. Hollister LE, Overall JE, Bennett JL, Kimbell I, Shelton J. Specific therapeutic actions of acetophenazine, perphenazine, and benzquinamide in newly admitted schizophrenic patients. Clinical Pharmacology and Therapeutics 1967;8(2):249-55.
205. Kellam AMP, Jones KS. A double-blind controlled trial of thiothixene and perphenazine in chronic schizophrenics shown to require maintenance therapy. Acta Psychiatrica Scandinavica 1971;47(2):174-85.
206. Mahmoud RA, Engelhart LM, Janagap CC, Oster G, Ollendorf D. Risperidone versus conventional antipsychotic drugs for schizophrenia and schizoaffective disorder: symptoms, quality of life and resource use under customary clinical care. Clinical drug investigation 2004; Vol. 24, issue 5:275-86. [MAHMOUD: 2004 a]
207. NCT. Decision aid to facilitate shared decision making during treatment in schizophrenia. http://ClinicalTrials.gov/show/NCT01420575 2011. [: NCT01420575]
208. Povlsen UJ, Noring U, Meidahl B, Korsgaard S, Waehrens J, Gerlach J. The effects of neuroleptics on tardive dyskinesias. A video-controlled, randomized study of chlorprothixene, perphenazine, haloperidol and haloperidol + biperiden [Neuroleptikas virkning pa tardive dyskinesier. En videokontrolleret, randomiseret undersogelse med klorprotixen, perfenazin, haloperidol og haloperidol+biperiden]. Ugeskrift for Laeger 1987;149(25):1682-5.
209. Schulsinger F, Jensen R. Trilafon (perphenazine) and largactil (chlorpromazine) in chronic schizophrenia. A comparison [Trilafon (perfenazin) og largactil (klorpromazin) hos kronisk sindssyge. En sammenligning]. Ugeskrift for Laeger 1958;120(12):366-9.
210. Szafranski T, Jarema M, Olajossy M, Chrzanowski W, Araszkiewicz A, Landowski J, et al. Subjective experiences of schizophrenic patients on atypical antipsychotic olanzapine and typical antipsychotic perphenazine. Journal of the European College of Neuropsychopharmacology 1999;9:273.
211. Vinar O. Differences in therapeutic effects of phenothiazine drugs. Agressolgie 1968;9(2):315-7.
212. Altman DG, Bland JM. Detecting skewness from summary information. BMJ 1996;313:1200.
213. Begg C, Cho M, Eastwood S, Horton R, Moher D, Ollon I, et al. Improving the quality of reporting of randomized controlled trials. The CONSORT statement [comment]. JAMA 1996;276:637-9.
214. Benkert O, Hippius H. Psychiatrische Pharmakotherapie. 6th Edition. Berlin: Springer Verlag, 1996.
215. Bland JM, Kerry SM. Trials in clusters. BMJ 1997;315:600.
216. Bleuler E. [The prognosis of dementia praecox - schizophrenia group - Google translate] [Die Prognose der Dementia praecox - Schizophreniegruppe]. Allgemeine Zeitschrift für Psychiatrie 1908;65:436-64.
217. BMJ Group and Pharmaceautical Press. British National Formulary No. 63. Antipsychotic drugs. BNF 2012.
218. Boissel JP, Cucherat M, Li W, Chatellier G, Gueyffier F, Buyse M, et al. The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use [Apercu sur la problematique des indices d'efficacite therapeutique, 3: comparaison des indices et utilisation. Groupe d'Etude des Indices D'efficacite]. Therapie 1999;54(4):405-11. [PUBMED: 10667106]
219. Bundesverband der Pharmazeutischen Industrie (editors). No English title given [Fachinformation Decentan]. Fachinformation Decentan 2001:1-4.
220. Cannon M, Jones P. Schizophrenia. Journal of Neurology, Neurosurgery and Psychiatry 1996;61:604-13.
221. Cost-Effectiveness Analysis Registry (CEA). https://research.tufts-nemc.org/cear4/ accessed 11/09/13.
222. Clarke M, Oxman AD. Cochrane Reviewers' Handbook. The Cochrane Library [database on disk and CDROM]. Oxford: Update Software, 2000.
223. David A, Quraishi SN, Rathbone J. Depot perphenazine decanoate and enanthate for schizophrenia. Cochrane Database of Systematic Reviews 2005, Issue 3. [DOI: ]
224. Davies LM, Lewis S, Jones PB, Barnes TR, Gaughran F, Hayhurst K, et al. Cost-effectiveness of first- v. second-generation antipsychotic drugs: results from a randomised controlled trial in schizophrenia responding poorly to previous therapy. British Journal of Psychiatry 2007;191:14-22.
225. Deeks J. Issues in the selection for meta-analyses of binary data. Abstracts of the 8th International Cochrane Colloquium. Cape Town, South Africa: Cochrane Collaboration, 2000 Oct 25th-29th.
226. Divine GW, Brown JT, Frazer LM. The unit of analysis error in studies about physicians' patient care behavior. Journal of General Internal Medicine 1992;7:623-9.
227. Donner A, Klar N. Issues in the meta-analysis of cluster randomized trials. Statistics in Medicine 2002;21:2971-80.
228. Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629-34.
229. Elbourne D, Altman DG, Higgins JPT, Curtina F, Worthingtond HV, Vaile A. Meta-analyses involving cross-over trials: methodological issues. International Journal of Epidemiology 2002;31(1):140-9.
230. Furukawa TA, Barbui C, Cipriani A, Brambilla P, Watanabe N. Imputing missing standard deviations in meta-analyses can provide accurate results. Journal of Clinical Epidemiology 2006;59(7):7-10.
231. Gulliford MC, Ukoumunne OC, Chinn S. Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994. American Journal of Epidemiology 1999;149:876-83.
232. Guy W. ECDEU Assessment Manual for Psychopharmacology. Rockville, MD: National Institute of Mental Health. DHEW Publication NO (ADM), 1976:124-585.
233. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-60.
234. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
235. Hutton JL. Number needed to treat and number needed to harm are not the best way to report and assess the results of randomised clinical trials. British Journal of Haematology 2009;146(1):27-30.
236. ICH Expert Working Group. ICH harmonised tripartite guideline: structure and content of clinical study reports. International conference on harmonisation of technical requirements for registration of pharmaceuticals for huma use 30 November 1995.
237. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJM, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Controlled Clinical Trials. Vol. 17, New York: Elsevier, 1996:1-12.
238. Kay SR, Opler LA, Fiszbein A. Positive and Negative Syndrome Scale (PANSS) Manual. North Tonawanda, NY: Multi-Health Systems, 1986.
239. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophrenia Bulletin 1987;13:261-76.
240. Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel RR. What does the PANSS mean?. Schizophrenia Research 2005;79(2-3):231-8. [PUBMED: 15982856]
241. Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel R. Clinical implications of brief psychiatric rating scale scores. British Journal of Psychiatry 2005;187:366-71. [PUBMED: 16199797]
242. Leucht S, Engel RR, Bauml J, Davis JM. Is the superior efficacy of new generation antipsychotic drugs an artifact of LOCF?. Schizophrenia Bulletin 2007;33(1):183-91. [PUBMED: 16905632]
243. Lowe GR. The phenomenology of hallucinations as an aid to differential diagnosis. British Journal of Psychiatry 1973;123:621-33.
244. Mangalore R, Knapp M. Cost of schizophrenia in England. Journal of Mental Health Policy and Economics 2007;10(1):23-41.
245. Marshall M, Lockwood A, Bradley C, Adams C, Joy C, Fenton M. Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia. British Journal of Psychiatry 2000;176:249-52.
246. Moher D, Schultz KF, Altman DG. The CONSORT statement: revised recommendations for improving the quality of reports of parallel group randomised trials. Lancet 2001;357:1191-4.
247. National Collaborating Centre for Mental Health. Schizophrenia: core interventions in the treatment and management of schizophrenia in adults in primary and secondary care (updated edition). National Clinical Guideline Number 82 2010.
248. Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychological Reports 1962;10:799-812.
249. Parfitt K (editor). Martindale. The Complete Drug Reference. 2nd Edition. London: Pharmaceutical Press, 1999.
250. Rosenheck RA, Davis VG, Davis SM, Stroup S, McEvoy J, Swartz M, et al. Can a nonequivalent choice of dosing regimen bias the results of flexible dose double blind trials? The CATIE schizophrenia trial. Schizophrenia Research 2009;113(1):12-8.
251. Schünemann HJ, Oxman AD, Vist GE, Higgins JPT, Deeks JJ, Glasziou P, et al. Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions. The Cochrane Collaboration, 2008:359-83.
252. Ukoumunne OC, Gulliford MC, Chinn S, Sterne JAC, Burney PGJ. Methods for evaluating area-wide and organisation-based interventions in health and health care: a systematic review. Health Technology Assessment 1999;3(5):iii-92. [MEDLINE: 10982317]
253. Wing J. A simple and reliable subclassification of chronic schizophrenia. British Journal of Psychiatry 1967;107:862-75. [DOI: ]
254. Xia J, Adams CE, Bhagat N, Bhagat V, Bhoopathi P, El-Sayeh H, et al. Loss to outcomes stakeholder survey: the LOSS study. Psychiatric Bulletin 2009;33(7):254-7.
255. Hartung B, Wada M, Laux G, Leucht S. Perphenazine for schizophrenia. Cochrane Database of Systematic Reviews 2005, Issue 1. [DOI: ]